Cellect Biotech stock rises 71% after announcing successful stem cell transplant procedure – MarketWatch
Investopedia |
Cellect Biotech stock rises 71% after announcing successful stem cell transplant procedure
MarketWatch Cellect Biotechnology Ltd. ADR APOP, +83.26% shares rose 71.3% in heavy volume after the company said on Monday that it had completed the first stem cell transplant procedure in an early/mid-stage clinical trial. The Israel-based biotech said the … Cellect Succeeds In First Stem Cell Transplant (APOP) Cellect (APOP) Reports First Successful Stem Cell Transplant Procedure Using its ApoGraft Technology Cellect Biotech Up 65% After Stem Cell Transplant Completed In Phase I/II Trial |
